Wave Life Sciences Ltd (NASDAQ:
WVE) is one of the
13 Best Revenue Growth Stocks to Buy Right Now.
On February 2, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, a rare genetic disorder, from GSK. There are currently no approved therapies to address the lung and liver manifestations of the disease. It is one of the largest rare-disease indications, affecting 200,000 individuals in the U.S. and Europe.
A lab technician in a biopharmaceutical laboratory, surrounded by technology and equipment necessary for advanced research.
Wave Life said it is accelerating its strategy for the drug and plans to meet with the U.S. Food and Drug Administration on a potential accelerated approval pathway, with regulatory feedback expected mid-2026.
The collaboration between Wave Life and GSK continues, under which Wave Life is eligible for up to $2.8 billion in initiation, development, launch, and commercialization milestones, as well as tiered royalties. Its cash runway is sufficient to fund operations into the third quarter of 2028.
On the same day, Wedbush analyst Yun Zhong maintained a Buy rating on the company’s stock with a price target of $33.
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, pioneering RNA-based genetic medicines using its proprietary PRISM platform for stereopure oligonucleotides.
While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy.
Disclosure: None. This article is originally published at
Insider Monkey.
